Bulgarie - bulgare - БАБХ (Българска агенция по безопасност на храните)

ceva sante animale - Тиамулина гидроген фумарат - перорален разтвор - 125.0 mg/ml - прасета, птици

Bulgarie - bulgare - БАБХ (Българска агенция по безопасност на храните)

virbac - Тилетамин (под формата на хидрохлорид); zolazepam (под формата на хидрохлорид) - инжекционен разтвор - 250 mg/флакон; 250 mg/флакон - котки, кучета

Bulgarie - bulgare - БАБХ (Българска агенция по безопасност на храните)

virbac - Тилетамин (под формата на хидрохлорид); zolazepam (под формата на хидрохлорид) - инжекционен разтвор - 125 mg/флакон; 125 mg/флакон - котки, кучета

Union européenne - bulgare - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - монохидрат Имипенем, циластатин натрий, relebactam монохидрат - Грамотрицательные Бактериални Инфекции - carbapenems, antibacterials for systemic use, - recarbrio is indicated for:- treatment of hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap), in adults (see sections 4. 4 и 5. - treatment of bacteraemia that occurs in association with, or is suspected to be associated with hap or vap, in adults. - treatment of infections due to aerobic gram-negative organisms in adults with limited treatment options (see sections 4. 2, 4. 4 и 5. Трябва да се вземат предвид официалните препоръки за правилното използване на антибактериални агенти.

Union européenne - bulgare - EMA (European Medicines Agency)

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - Антинеопластични средства - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.

Union européenne - bulgare - EMA (European Medicines Agency)

curium pet france - piflufolastat (18f) - Простатни неоплазми - Диагностични радиофармацевтици - Този лекарствен продукт е само за диагностична употреба. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).